Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With HBeAg-negative Chronic Hepatitis B Treated With Nucleos(t)Ide Analogues

NCT07246889 is registered in ClinicalTrials.gov with Ausper Biopharma Co., Ltd. as lead sponsor.

NCT NCT07246889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07246889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With HBeAg-negative Chronic Hepatitis B Treated With Nucleos(t)Ide Analogues
Lead sponsor
Ausper Biopharma Co., Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 12, 2025
Completion date
October 31, 2027
Enrollment
577 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b